Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Ruth Salim1,2, Christian Winther Eskelund1,2, Mats Jerkeman3
1Department of Hematology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark.
A new circular RNA-based risk score, circSCORE, shows prognostic potential for patients with relapsed/refractory mantle cell lymphoma (MCL). This biomarker may help predict outcomes in both nodal and non-nodal tissues, offering a promising tool for R/R MCL management.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Mantle cell lymphoma (MCL) is a heterogeneous lymphoid malignancy.
- Optimal prognostic biomarkers for relapsed/refractory (R/R) MCL are lacking.
- Circular RNA-based risk score (circSCORE) shows promise in newly diagnosed MCL.
Purpose of the Study:
- To evaluate the prognostic value of circSCORE in R/R MCL.
- To assess circSCORE's utility in nodal (lymph node) and non-nodal (bone marrow, peripheral blood) tissues.
- To determine if circSCORE retains prognostic significance when adjusted for established markers.
Main Methods:
- RNA extracted from 65 R/R MCL relapse samples (20 LN, 34 BM, 11 PB).
- circSCORE calculated and patients stratified into high-risk and low-risk groups.
- Kaplan-Meier and Cox regression analyses used to assess survival outcomes (PFS, OS).
Main Results:
- High-risk circSCORE associated with significantly inferior progression-free survival (PFS) (HR 1.99, p=0.0407) and overall survival (OS) (HR 2.29, p=0.0192).
- Similar trends observed in non-nodal tissue samples.
- circSCORE remained a significant prognostic factor for PFS after adjusting for Ki67, MIPI, and TP53 mutation status.
Conclusions:
- circSCORE demonstrates prognostic potential in R/R MCL.
- circSCORE shows promise for application in non-nodal tissues like bone marrow and peripheral blood.
- circSCORE may serve as an easily accessible biomarker for R/R MCL, pending further validation.
More Related Videos
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers
Cancer Survival Analysis
